ES2086309T3 - Medicamento que contiene un inhibidor del tnf. - Google Patents

Medicamento que contiene un inhibidor del tnf.

Info

Publication number
ES2086309T3
ES2086309T3 ES89109312T ES89109312T ES2086309T3 ES 2086309 T3 ES2086309 T3 ES 2086309T3 ES 89109312 T ES89109312 T ES 89109312T ES 89109312 T ES89109312 T ES 89109312T ES 2086309 T3 ES2086309 T3 ES 2086309T3
Authority
ES
Spain
Prior art keywords
tnf inhibitor
product containing
medicinal product
tnf
contain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89109312T
Other languages
English (en)
Inventor
Heinz Dr Hanel
Elmar Dr Schrinner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taiho Pharmaceutical Co Ltd
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2086309T3 publication Critical patent/ES2086309T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LOS MEDICAMENTOS QUE CONTIENEN UNA SUSTANCIA LIBERADORA DEL FACTOR DE NECROSIS DE TUMOR (TNF).SON MAS TOLERABLES Y SE PUEDEN ANMINISTRAR EN DOSIS MAS ALTAS SI TIENEN UN COINTENIDO EN UN INHIBIDOR DE TNF, EN ESPECIAL UN DERIVADO DE XANTINA.
ES89109312T 1988-05-27 1989-05-24 Medicamento que contiene un inhibidor del tnf. Expired - Lifetime ES2086309T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3817955A DE3817955A1 (de) 1988-05-27 1988-05-27 Tnf-inhibitor enthaltendes arzneimittel

Publications (1)

Publication Number Publication Date
ES2086309T3 true ES2086309T3 (es) 1996-07-01

Family

ID=6355195

Family Applications (1)

Application Number Title Priority Date Filing Date
ES89109312T Expired - Lifetime ES2086309T3 (es) 1988-05-27 1989-05-24 Medicamento que contiene un inhibidor del tnf.

Country Status (9)

Country Link
US (1) US5118500A (es)
EP (1) EP0344586B1 (es)
JP (1) JP3140021B2 (es)
AT (1) ATE135225T1 (es)
DE (2) DE3817955A1 (es)
DK (1) DK258989A (es)
ES (1) ES2086309T3 (es)
GR (1) GR3020101T3 (es)
PT (1) PT90660B (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672347A (en) * 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
US5196430A (en) * 1986-12-31 1993-03-23 Hoechst-Roussel Pharmaceuticals Inc. Method of inhibiting the activity of leukocyte derived cytokines
US4965271A (en) * 1986-12-31 1990-10-23 Hoechst Roussel Pharmaceuticals, Inc. Method of inhibiting the activity of leukocyte derived cytokines
US5196429A (en) * 1986-12-31 1993-03-23 Hoechst-Roussel Pharmaceuticals Inc. Method of inhibiting the activity of leukocyte derived cytokines
US5272153A (en) * 1986-12-31 1993-12-21 Hoechst-Roussel Pharmaceuticals, Inc. Method of inhibiting the activity of leukocyte derived cytokines
US6541610B1 (en) 1989-09-05 2003-04-01 Immunex Corporation Fusion proteins comprising tumor necrosis factor receptor
DE59010908D1 (de) 1989-09-12 2000-08-10 Hoffmann La Roche TNF-bindende Proteine
DE4019571A1 (de) * 1990-06-20 1992-01-02 Hoechst Ag Pharmazeutische kombinationspraeparate enthaltend cephalosporin- und xanthinderivate und deren verwendung
AU9084991A (en) * 1990-11-01 1992-05-26 Board Of Regents, The University Of Texas System Antifungal activity of and prevention of drug induced nephrotoxicity by methylxanthine analogues
US5958413A (en) * 1990-11-01 1999-09-28 Celltech Limited Use of antibodies to TNF or fragments derived thereof and xanthine derivatives for combination therapy and compositions therefor
NZ240644A (en) * 1990-11-21 1994-08-26 Smithkline Beecham Corp Use of xanthine derivatives to inhibit the production of tumour necrosis factor (tnf)
IL100194A0 (en) * 1990-11-30 1992-08-18 Hoechst Roussel Pharma Use of xanthines for the preparation of a medicament effective for inhibiting the effects of allograft reaction in humans
US6420374B1 (en) 1990-11-30 2002-07-16 Fred Hutchinson Cancer Research Center Use of xanthines as immunosuppressants and to inhibit allograft reactions
US5856115A (en) * 1991-05-24 1999-01-05 Fred Hutchinson Cancer Research Center Assay for identification therapeutic agents
DE69232586T2 (de) * 1991-07-05 2002-11-28 Peptech Ltd., North Ryde Giftigkeit von tnf und lps ausschaltende peptide
ES2038546B1 (es) * 1991-11-08 1994-02-16 Andromaco Lab Procedimiento de obtencion de un producto de naturaleza polipeptidica con actividad inhibidora de la hiperproduccion del factor de necrosis tumoral.
CA2112239C (en) * 1992-03-04 2000-05-09 James A. Bianco Enantiomeric hydroxylated xanthine compounds
US5567704A (en) * 1992-03-04 1996-10-22 Cell Therapeutics, Inc. R-enatiomerically pure hydroxylated xanthine compounds to treat baldness
US5648357A (en) * 1992-03-04 1997-07-15 Cell Therapeutics, Inc. Enatiomerically pure hydroxylated xanthine compounds
DE69333027T2 (de) * 1992-03-30 2004-05-06 Immunex Corp., Seattle Fusionsprotein , das zwei rezeptoren des tumornekrose-faktors enthält
PL173978B1 (pl) * 1992-07-13 1998-05-29 Nika Health Products Ltd Sposób oddziaływania na wydzielanie cytokin w hodowli limfocytów krwi obwodowej
US6183742B1 (en) 1992-07-13 2001-02-06 Nika Health Products, Limited Applications of lysozyme dimer
US5817662A (en) * 1992-11-09 1998-10-06 Cell Therapeutics, Inc. Substituted amino alkyl compounds
US6693105B1 (en) 1992-11-16 2004-02-17 Cell Therapeutics, Inc. Hydroxyl-containing compounds
US5780476A (en) * 1992-11-16 1998-07-14 Cell Therapeutics, Inc. Hydroxyl-containing xanthine compounds
US5795897A (en) * 1992-11-18 1998-08-18 Cell Therapeutics, Inc. Oxohexyl methylxanthine compounds
AU6087894A (en) * 1993-01-14 1994-08-15 Cell Therapeutics, Inc. Acetal or ketal substituted therapeutic compounds
WO1994016704A1 (en) * 1993-01-19 1994-08-04 Cell Therapeutics, Inc. Oxime-substituted therapeutic compounds
WO1995013075A1 (en) * 1993-11-12 1995-05-18 Cell Therapeutics, Inc. Method for preventing tissue injury from hypoxia
US6103730A (en) * 1994-03-24 2000-08-15 Cell Therapeutics, Inc. Amine substituted compounds
JPH09511496A (ja) * 1994-02-18 1997-11-18 セル・セラピューティックス・インコーポレーテッド 細胞内メッセンジャー
US5801182A (en) * 1994-03-24 1998-09-01 Cell Therapeutics, Inc. Amine substituted compounds
US5807861A (en) * 1994-03-24 1998-09-15 Cell Therapeutics, Inc. Amine substituted xanthinyl compounds
US6010711A (en) * 1996-01-26 2000-01-04 University Of Rochester Methods, articles and compositions for the pharmacologic inhibition of bone resorption with phosphodiesterase inhibitors
DE19707655A1 (de) * 1997-02-26 1998-08-27 Hoechst Ag Kombinationspräparat zur Anwendung bei Demenz
US6123937A (en) * 1997-03-14 2000-09-26 Nika Health Products, Limited Applications of lysozyme dimer
US20030207901A1 (en) * 1999-07-27 2003-11-06 Cell Therapeutics, Inc. Hydroxyl-containing compounds
EP1282435A2 (en) * 2000-05-12 2003-02-12 Immunex Corporation Interleukin-1 inhibitors in the treatment of diseases
RU2184544C1 (ru) * 2000-12-08 2002-07-10 Институт иммунологии Противоаллергический препарат
US7101978B2 (en) * 2003-01-08 2006-09-05 Applied Molecular Evolution TNF-α binding molecules
US7892563B2 (en) * 2003-05-20 2011-02-22 Wyeth Holdings Corporation Methods for treatment of severe acute respiratory syndrome (SARS)
US7435799B2 (en) * 2004-01-08 2008-10-14 Applied Molecular Evolution TNF-α binding molecules
CA2560889A1 (en) * 2004-03-23 2005-10-13 Sanjay D. Khare Monoclonal antibodies specific for human ox40l (cd 134l)
CN113272320A (zh) 2018-11-19 2021-08-17 得克萨斯大学体系董事会 自杀基因

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4879111A (en) * 1986-04-17 1989-11-07 Cetus Corporation Treatment of infections with lymphokines

Also Published As

Publication number Publication date
ATE135225T1 (de) 1996-03-15
EP0344586B1 (de) 1996-03-13
DE58909621D1 (de) 1996-04-18
DE3817955A1 (de) 1989-11-30
JPH0219327A (ja) 1990-01-23
JP3140021B2 (ja) 2001-03-05
EP0344586A2 (de) 1989-12-06
PT90660A (pt) 1989-11-30
PT90660B (pt) 1994-10-31
US5118500A (en) 1992-06-02
GR3020101T3 (en) 1996-08-31
EP0344586A3 (en) 1990-05-16
DK258989A (da) 1989-11-28
DK258989D0 (da) 1989-05-26

Similar Documents

Publication Publication Date Title
DE58909621D1 (de) TNF-Inhibitor enthaltendes Arzneimittel
AU1687388A (en) Cough/cold mixtures comprising non-sedating antihistamine drugs
ES2161690T3 (es) Formulaciones farmaceuticas.
SE8503762L (sv) Analgetiska och anti-inflammatoriska kompositioner innefattande xantiner och forfarande for anvendning av dessa
NO160330C (no) Anordning for aa administrere medikamenter til pasienter og medikamentpakning for anordningen.
ES2120972T3 (es) Liposoma unido a una proteina y que contiene un medicamento.
IT8921132A0 (it) Inalatore per medicamenti in capsule.
ES2094923T3 (es) Procedimiento de preparacion de medicamentos conservados que contienen proteinas humanas, para fines de infusion o inyeccion.
DK462486A (da) Farmaceutisk tablet indeholdende cefuroxim-axetil
IL90435A (en) 4-(quinoline-2-yl-methoxy) phenylacetic acid derivatives, their preparation and pharmaceutical compositions containing them
SE8701900L (sv) Pulsavgivning av lekemedel
NO307864B1 (no) Farmasøytisk aerosolformulering, boks og doseringsinhalator
DE3873879D1 (de) Nicht-sedative antihistaminica enthaltende husten-/schnupfenmittel.
NO306377B1 (no) Doseform for avgivelse av et medikament
DE68900378D1 (de) Ibuprofen in kombination mit einem piperidinylalkanolantihistaminikum enthaltenden arzneimittel.
ATE89721T1 (de) L-carnitin-haltige zubereitungen.
DE3480599D1 (de) 1-hydroxypyrid-2-on-derivate enthaltende pharmazeutische zubereitungen.
DE68914644D1 (de) Verringerung der nebeneffekte bei der krebstherapie.
HUT39603A (en) Process for producing pharmaceutical compositions containing synergistic combinations of flupirtin and nonsteroide antiphlogistics
FI905684A0 (fi) Farmaceutisk doseringsform foer utdelning av medicin aot fiskar.
DE68917499D1 (de) Catechol-Derivate und sie enthaltende pharmazeutische Präparate.
ATE69164T1 (de) Arzneimittel zur behandlung von uraemie.
ES2093779T3 (es) Formulacion farmaceutica que contiene diritromicina.
AU7999787A (en) Active compounds for use in the treatment of tumors
KR900007816A (ko) 사이클로프로필-치환된 아졸릴메틸카비놀, 이의 제조방법 및 약제로서의 이의 용도

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 344586

Country of ref document: ES